NCT04077567View on ClinicalTrials.gov

An Extension Study of TS-152 in Subjects with Rheumatoid Arthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

401

Participants

Timeline

Start Date

October 1, 2019

Primary Completion Date

April 28, 2023

Study Completion Date

April 28, 2023

Conditions
Rheumatoid Arthritis
Interventions
DRUG

TS-152

30mg,80mg

Trial Locations (1)

Unknown

Taisho Pharmaceutical Co., Ltd selected site, Tokyo

All Listed Sponsors
lead

Taisho Pharmaceutical Co., Ltd.

INDUSTRY

NCT04077567 - An Extension Study of TS-152 in Subjects with Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter